08/14/2025
10:43 AM | JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
08/12/2025
3:34 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/11/2025
6:25 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/07/2025
6:04 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/01/2025
3:04 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/11/2025
5:17 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/10/2025
4:08 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2025
8:28 AM | Ligand Pharmaceuticals (Reporting)
Pelthos Therapeutics Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
07/03/2025
8:33 AM | Ligand Pharmaceuticals (Reporting)
Pelthos Therapeutics Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2025
6:31 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2025
6:32 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for LGND and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
07/02/2025
6:32 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2025
6:03 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 3/A | |
07/02/2025
6:10 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/24/2025
7:29 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/23/2025
4:07 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/12/2025
4:51 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/10/2025
6:39 PM | Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/10/2025
6:39 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/10/2025
6:20 PM | Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/10/2025
6:21 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/10/2025
6:21 PM | Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/10/2025
6:21 PM | Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/10/2025
6:24 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/10/2025
5:49 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/02/2025
7:05 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/02/2025
7:06 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/14/2025
11:31 AM | JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
05/13/2025
7:04 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/13/2025
7:05 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/08/2025
6:06 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/17/2025
5:08 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/16/2025
8:34 AM | Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2025
5:54 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2025
5:55 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2025
5:55 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/28/2025
3:02 PM | Ligand Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/27/2025
6:06 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/19/2025
7:44 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
7:37 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/19/2025
7:38 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
New law could create $3.7 trillion tsunami. (Ad) During a meeting in Washington D.C., Jeff Brown discovered a bold initiative.
He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard.
The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.”
Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. You can watch it right here. |
02/14/2025
11:36 AM | JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
12/26/2024
7:32 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/23/2024
7:19 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/06/2024
6:55 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/02/2024
7:05 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/27/2024
3:44 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/14/2024
2:19 PM | JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/08/2024
4:34 PM | GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024
6:11 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2024
3:07 PM | Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
| Form SC 13G/A | |
09/25/2024
7:54 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/24/2024
6:41 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/24/2024
6:41 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/23/2024
4:27 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/23/2024
4:30 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/20/2024
5:12 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/20/2024
4:39 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/19/2024
4:50 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
6:55 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2024
8:00 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2024
7:56 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/28/2024
3:39 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024
7:15 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/22/2024
5:05 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
MarketBeat All Access